iX Biopharma Ltd. (SG:42C) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
iX Biopharma is escalating its efforts to out-license Wafermine, its non-opioid pain treatment with potential applications in Complex Regional Pain Syndrome and depressive disorders, by partnering with the global life sciences advisory firm Kybora. The company is setting its sights on global markets, banking on Wafermine’s US FDA Orphan Drug Designation, which promises 7 years of market exclusivity and development incentives. With a focus on safety and effectiveness, Wafermine represents a promising alternative to opioid painkillers and a potential breakthrough for treatment-resistant depression.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.